234
Participants
Start Date
October 27, 2022
Primary Completion Date
August 21, 2023
Study Completion Date
August 21, 2023
PP-01 High Dose
Cannabinoid-1 (CB1) partial agonist / GABAergic modulator
PP-01 Low Dose
CB1 partial agonist / GABAergic modulator
Placebo
Placebo comparator
Nabilone
CB1 receptor
Gabapentin
GABAergic modulator
Medical University of South Carolina, Charleston
CenExel iResearch Atlanta, LLC, Decatur
CenExel iResearch Savannah, LLC, Savannah
CNS Clinical Research Group, Coral Springs
Innovative Clinical Research Inc., Lauderhill
Gulf Coast Clinical Research, Fort Myers
Otrimed Research Center, Edgewood
North Star Medical Research, Middleburg Heights
Pillar Clinical Research, LLC, Chicago
Tandem Clinical Research, Marrero
Benchmark Research, Shreveport
Pahl Pharmaceutical Professionals LLC, Oklahoma City
Austin Clinical Trials, Austin
Cedar Clinical Research, Draper
Behavioral Research Specialists, LLC, Glendale
Synergy San Diego, Lemon Grove
Neuropsychiatric Research Institute, Orange
Hassman Research Institute, Berlin
Lead Sponsor
PleoPharma, Inc.
INDUSTRY